Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

BLU-285 for advanced systemic mastocytosis

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.12.17
Views: 2174
Rating:

Prof Daniel DeAngelo - Dana-Farber Cancer Institute, Boston, USA

Prof DeAngelo talks with ecancer at the 2017 ASH annual meeting about the phase 1 study of BLU-285, a highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis. 

Prof DeAngelo highlights that BLU-285 demonstrated significant clinical activity across all dose levels, with rapid and durable reductions in mast cell burden and D816V mutant allele fraction relative to baseline.

Read the news story or watch the press conference for more.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Donate to ecancer


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation